Cartilage Degeneration - Pipeline Review, H1 2014

Cartilage Degeneration - Pipeline Review, H1 2014

Regular price $2,000.00 Sale

Published on May 30, 2014 - 37 pages

Global Markets Direct's, 'Cartilage Degeneration - Pipeline Review, H1 2014', provides an overview of the Cartilage Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cartilage Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cartilage Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Cartilage Degeneration
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cartilage Degeneration and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cartilage Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cartilage Degeneration
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cartilage Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cartilage Degeneration Overview
Therapeutics Development
Pipeline Products for Cartilage Degeneration - Overview
Pipeline Products for Cartilage Degeneration - Comparative Analysis
Cartilage Degeneration - Therapeutics under Development by Companies
Cartilage Degeneration - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Cartilage Degeneration - Products under Development by Companies
Cartilage Degeneration - Companies Involved in Therapeutics Development
Merck KGaA
Mesoblast Limited
Calzada Limited
Thrasos, Inc.
Cartilage Degeneration - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
sprifermin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chondrogen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MSB-CAR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AOD-9604 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THR-166 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cartilage Degeneration - Recent Pipeline Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cartilage Degeneration, H1 2014
Number of Products under Development for Cartilage Degeneration - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Cartilage Degeneration - Pipeline by Merck KGaA, H1 2014
Cartilage Degeneration - Pipeline by Mesoblast Limited, H1 2014
Cartilage Degeneration - Pipeline by Calzada Limited, H1 2014
Cartilage Degeneration - Pipeline by Thrasos, Inc., H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014


Companies Mentioned:

Merck KGaA
Mesoblast Limited
Calzada Limited
Thrasos, Inc.